NCT01628926View on ClinicalTrials.gov

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

SPM 962

SPM 962 transdermal patch once a daily up to 36.0 mg/day

DRUG

Ropinirole

Ropinirole oral administration TID up to 15.0 mg/day

DRUG

Placebo

SPM962-placebo patch and Ropinirole-placebo tab

Trial Locations (8)

Unknown

Chubu Region

Chugoku Region

Hokkaido Region

Kanto Region

Kinki Region

Kyushu Region

Shikoku Region

Tohoku Region

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY